BioVaxys Technology (BioVaxys Technology) EBIT : $-2.36 Mil (TTM As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology EBIT?

BioVaxys Technology's earnings before interest and taxes (EBIT) for the three months ended in Jul. 2023 was $-0.43 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jul. 2023 was $-2.36 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioVaxys Technology's annualized ROC % for the quarter that ended in Jul. 2023 was -232.88%. BioVaxys Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioVaxys Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2023 was -29.91%.

BioVaxys Technology EBIT Historical Data

The historical data trend for BioVaxys Technology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology EBIT Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

EBIT

-0.17

-0.83

-5.18

-2.98

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
EBIT	Get a 7-Day Free Trial															-0.70	-0.68	-0.68	-0.58	-0.43

Competitive Comparison of BioVaxys Technology's EBIT

For the Biotechnology subindustry, BioVaxys Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's EV-to-EBIT falls into.

BioVaxys Technology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.36 Mil.

BioVaxys Technology (OTCPK:BVAXF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BioVaxys Technology's annualized ROC % for the quarter that ended in Jul. 2023 is calculated as:

	ROC % (Q: Jul. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Apr. 2023 )	+	Invested Capital (Q: Jul. 2023 ))	/ count )
=	-1.7 * ( 1 - 0% )	/	( (1.102	+	0.358)	/ 2 )
=	-1.7	/	0.73
=	-232.88 %

where

	Invested Capital		(Q: Apr. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.968	-	1.302	-	( 0.021	-	max(0, 1.302	-	0.866	+	0.021	))
=	1.102

	Invested Capital		(Q: Jul. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.07	-	1.542	-	( 0	-	max(0, 1.542	-	0.712	+	0	))
=	0.358

Note: The Operating Income data used here is four times the quarterly (Jul. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

BioVaxys Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jul. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Apr. 2023		Q: Jul. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.7	/	( ( (0 + max(-0.647, 0))	+	(0 + max(-1.027, 0)) )	/	2 )
=	-1.7	/	( ( 0	+	0 )	/	2 )
=	-1.7	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Apr. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.655)	-	(1.302	+	0	+	0)
=	-0.647

	Working Capital		(Q: Jul. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.515)	-	(1.542	+	0	+	0)
=	-1.027

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jul. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BioVaxys Technology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jul. 2023 )
	=	-2.363	/	7.901
	=	-29.91 %

BioVaxys Technology EBIT Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.